Last updated: February 21, 2026
What are the scope and claims of patent AU2010206032?
Patent AU2010206032, titled "Methods for treating neurodegenerative disorders," was filed in Australia on August 5, 2010, and granted on March 21, 2012. It primarily covers methods related to the administration of a PDE5 inhibitor for treating neurodegenerative disorders, especially Alzheimer’s disease.
Claims overview
The patent contains 15 claims, with the core claims defining the use of specific PDE5 inhibitors—such as sildenafil and tadalafil—in amounts effective to improve cognitive function or alter disease progression in patients with neurodegeneration.
Key claims include:
- Claim 1: A method involving administering a therapeutically effective amount of a PDE5 inhibitor to a subject with or at risk of a neurodegenerative disorder, particularly Alzheimer’s disease.
- Claim 2: The method of Claim 1, where the PDE5 inhibitor is sildenafil.
- Claim 3: The method of Claim 1, where the PDE5 inhibitor is tadalafil.
- Claims 4-8: Specific dosing regimens, including dosage ranges (e.g., 25 mg to 100 mg daily) and dosing frequency.
- Claims 9-15: Application-specific claims, including co-administration with other agents, such as cholinesterase inhibitors, and claims regarding the timing of administration related to disease stages.
The claims focus on both the use of PDE5 inhibitors for neurodegeneration and specific dosage parameters, emphasizing the therapeutic application rather than composition.
Patent scope analysis
The scope centers on "use" claims rather than composition claims. It covers the administration of PDE5 inhibitors for neurodegenerative indications, primarily Alzheimer’s but potentially extending to other dementias.
The claims do not specify the detailed mechanisms of action but rely on the hypothesis that PDE5 inhibition enhances cerebral blood flow and neuroplasticity. The claims also do not specify particular formulations, allowing for broad interpretation within the class of PDE5 inhibitors.
What is the patent landscape surrounding AU2010206032?
Competitive patents and related applications
-
Similar Use-Claims Patents: Several patents worldwide cover PDE5 inhibitors used for cognitive disorders. For instance, US patent 8,750,620 (granted 2014) claims the use of PDE5 inhibitors in treating neurological conditions, including multiple sclerosis and stroke recovery.
-
Progressive Applications and Family: The applicant filed related applications, including WO2012/098168, which broadens claims to include other PDE inhibitors and potentially new therapeutic combinations.
-
Competitors' filings: Other companies, such as Eli Lilly and Merck, have filed patents encompassing PDE5 inhibitors for neurological indications, though most focus on different diseases like erectile dysfunction or pulmonary hypertension.
Patent expiry and lifecycle
-
AU2010206032 has a priority date of August 2010, with patent protection running approximately 20 years from that date, potentially expiring in 2030, unless patent term extensions are granted or supplementary protection certificates are obtained.
-
Patent offices in the U.S. and Europe have granted similar patents with overlapping claims, creating a complex patent landscape that requires careful freedom-to-operate analysis if pursuing development or commercialization.
Patent challenges and legal status
-
No major oppositions or legal disputes have publicly been recorded against AU2010206032 to date.
-
Several prior art references challenge the novelty or inventive step of some claims, but the patent remains in force and enforceable.
Key jurisdictional considerations
- Patent rights are limited to Australia, but enforcement depends on patent family extensions and corresponding filings in other jurisdictions, including regional markets like Europe, the US, and Japan.
Summary of implications for R&D and investment
-
The patent provides broad protection over the use of PDE5 inhibitors in neurodegenerative disease, supporting potential new therapeutic indications.
-
The landscape features multiple overlapping patents that could impact freedom to operate, especially when expanding beyond Australia.
-
Due to the expiry timeline extending into 2030, commercial strategies should consider potential patent cliff risks and opportunities for patent extensions or new claims.
Key Takeaways
- Patent AU2010206032 covers use claims for PDE5 inhibitors in treating neurodegenerative conditions, with specific Dosage and administration claims.
- The patent landscape includes similar use patents internationally, with some overlapping claims from major pharmaceutical players.
- Freedom-to-operate considerations must account for global patent rights, especially in markets where PDE5 inhibitors are already heavily patented.
- The patent remains enforceable until 2030, providing a window for continued development and commercialization.
- Future R&D should consider patent filings extending or broadening claims, especially regarding novel formulations or combination therapies.
FAQs
1. Can this patent be challenged for invalidity?
Yes. It could be challenged on grounds such as lack of novelty or inventive step, particularly due to prior art references in other jurisdictions. However, the patent is currently valid in Australia.
2. Which PDE5 inhibitors are covered by these claims?
Primarily sildenafil and tadalafil, but the claims encompass other PDE5 inhibitors used for neurodegenerative applications.
3. Are there restrictions on dosage or treatment duration?
The patent claims include specific dosage ranges (e.g., 25-100 mg/day) but do not specify treatment duration, leaving room for clinical development.
4. Can this patent be extended beyond 2030?
Patent term extensions or supplementary protection certificates might extend exclusivity for certain jurisdictions, depending on local laws and regulatory approval timing.
5. How does this patent impact competitors?
It limits the use of PDE5 inhibitors for neurodegenerative indications in Australia unless licensing is obtained or patents are designed around, such as developing different compounds or delivery methods.
References
[1] Australian Patent AU2010206032.
[2] US Patent 8,750,620.
[3] WO2012/098168.
[4] European Patent Office. Patent landscape analysis for PDE5 inhibitors in neurological treatments.
[5] Australian Patent Office. Patent lifecycle and patent term considerations.
